Citigroup Begins Coverage on Elanco Animal Health (NYSE:ELAN)

Research analysts at Citigroup started coverage on shares of Elanco Animal Health (NYSE:ELAN) in a research note issued on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $30.00 price target on the stock. Citigroup’s price objective would indicate a potential upside of 29.85% from the company’s previous close.

A number of other research firms have also recently commented on ELAN. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, February 19th. Finally, KeyCorp boosted their price target on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average target price of $27.90.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $23.10 on Wednesday. The stock has a market capitalization of $11.49 billion, a PE ratio of -48.13, a P/E/G ratio of 2.96 and a beta of 1.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The business has a fifty day moving average price of $24.37 and a two-hundred day moving average price of $23.07. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of ELAN. NewEdge Advisors LLC grew its position in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares during the last quarter. SJS Investment Consulting Inc. grew its position in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares during the last quarter. Huntington National Bank grew its position in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the last quarter. Root Financial Partners LLC grew its position in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $41,000. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.